Adverum Biotechnologies (ADVM)
(Delayed Data from NSDQ)
$10.66 USD
+0.23 (2.21%)
Updated May 6, 2024 04:00 PM ET
After-Market: $10.64 -0.02 (-0.19%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ADVM 10.66 +0.23(2.21%)
Will ADVM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ADVM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADVM
PetIQ (PETQ) Gears Up to Report Q1 Earnings: What's in Store?
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
ADVM: What are Zacks experts saying now?
Zacks Private Portfolio Services
ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
Adverum Biotechnologies (ADVM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for ADVM
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
Adverum Biotechnologies a new buy at H.C. Wainwright on wet AMD gene therapy
Analysts Are Bullish on Top Healthcare Stocks: Abbott Labs (ABT), Iterum Therapeutics (ITRM)
Adverum Biotechnologies initiated with bullish view at H.C. Wainwright, here's why
Adverum Biotechnologies management to meet with Truist